ReWalk Robotics (RWLK) Receives News Impact Score of 0.31
News stories about ReWalk Robotics (NASDAQ:RWLK) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ReWalk Robotics earned a daily sentiment score of 0.31 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- ReWalk Robotics to Present at Canaccord Genuity Growth Conference 2017 – GlobeNewswire (press release) (globenewswire.com)
- 3 Stocks Catching Momentum Off Dow Record Highs – Baystreet.ca (baystreet.ca)
- BUZZ-US STOCKS ON THE MOVE-Apple, AMC Entertainment, Terravia Holdings, Garmin – Nasdaq (nasdaq.com)
- ReWalk Robotics (RWLK) Says Foundational Study Shows Soft Suit Exoskeleton Improves Walking for Stroke Survivors – StreetInsider.com (streetinsider.com)
ReWalk Robotics (RWLK) traded up 7.14% during mid-day trading on Thursday, hitting $1.50. The stock had a trading volume of 528,073 shares. The stock’s market cap is $25.01 million. The firm’s 50-day moving average price is $1.58 and its 200-day moving average price is $1.77. ReWalk Robotics has a 1-year low of $1.10 and a 1-year high of $7.85.
ReWalk Robotics (NASDAQ:RWLK) last posted its earnings results on Thursday, August 3rd. The medical device company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.02. ReWalk Robotics had a negative return on equity of 496.02% and a negative net margin of 507.07%. The company had revenue of $2.01 million during the quarter, compared to the consensus estimate of $1.71 million. During the same period last year, the firm posted ($0.64) EPS. The company’s revenue for the quarter was up 145.7% on a year-over-year basis. On average, equities analysts expect that ReWalk Robotics will post ($1.44) earnings per share for the current year.
RWLK has been the subject of a number of recent research reports. Zacks Investment Research upgraded ReWalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Thursday, May 11th. Canaccord Genuity restated a “buy” rating on shares of ReWalk Robotics in a report on Monday, June 12th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $4.00 price objective (down from $7.00) on shares of ReWalk Robotics in a research report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $4.25.
ILLEGAL ACTIVITY WARNING: “ReWalk Robotics (RWLK) Receives News Impact Score of 0.31” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/03/rewalk-robotics-rwlk-given-coverage-optimism-rating-of-0-31-updated-updated-updated.html.
In other ReWalk Robotics news, major shareholder Scp Vitalife Partners (Israel) sold 9,271 shares of ReWalk Robotics stock in a transaction on Monday, June 26th. The shares were sold at an average price of $3.00, for a total value of $27,813.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeff Dykan sold 37,030 shares of ReWalk Robotics stock in a transaction on Monday, June 26th. The shares were sold at an average price of $3.00, for a total transaction of $111,090.00. The disclosure for this sale can be found here. Insiders have sold a total of 199,883 shares of company stock worth $604,772 in the last quarter. Corporate insiders own 13.70% of the company’s stock.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Stock Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related stocks with our FREE daily email newsletter.